Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VE7B
|
|||
| Drug Name |
DSP-2230
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Phase 1 | [1], [2] | |
| Company |
Sumitomo Dainippon Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H20F3N5O2
|
|||
| Canonical SMILES |
CC(C(=O)N)NCC1=NC2=C(N1C3CCC3)N=C(C=C2)OC4=CC(=C(C(=C4)F)F)F
|
|||
| InChI |
1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m0/s1
|
|||
| InChIKey |
HHXCJIMPEJSJTG-JTQLQIEISA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.7 (SCN9A) | Target Info | Inhibitor | [1], [2] |
| Voltage-gated sodium channel alpha Nav1.8 (SCN10A) | Target Info | Inhibitor | [1], [2] | |
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.